drugset / Trial / NCT00232687
A Switch Study of BMS-337039 in Schizophrenic Out-patients
Phase 4
Completed
450 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.
Timeline
- Start
- 2005-06-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 10 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 30 mg | Oral |